Prostate Cancer With Metastatic Lytic Bone Lesions: Positive Bone Scan Post Docetaxel Chemotherapy in the Setting of Clinically Successful Treatment

详细信息    查看全文

• 作者：Victoria Yvonne Bird^a ; ^{VICTORIA.BIRD@UROLOGY.UFL.EDU" class="auth_mail" title="E-mail the corresponding author} ; Paula M. Domino^b ; Raymond Sutkowski^c ; Stephanie A. Stillings^d ; Jorge A. Trejo-Lopez^e
• 关键词：Prostate ; Lytic ; Bone-scan ; Docetaxel
• 刊名：Urology Case Reports
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：6
• 期：Complete
• 页码：12-14
• 全文大小：766 K

文摘

Current treatment of metastatic bone prostate cancer with Docetaxel chemotherapy per CHAARTED trial is standard of care. Timing of CT and bone scintigraphy for evaluation of successful treatment of lytic lesions is not available in the literature. We present a case of a 70 year old male with PSA of 586 and wide spread metastatic bone lytic lesions, who underwent androgen deprivation therapy and six cycles of Docetaxel chemotherapy. The patient had clinically successful treatment. Contrast enhanced CT scan demonstrated sclerotic bone lesions with PSA 2.5 at this point in treatment; however, 99mTc-MDP bone scintigraphy remained positive for metastatic lesions.